Gene Therapies, CAR-T Cell Therapies, and other Advanced Therapy Medicinal Products (ATMPs) are advancing rapidly, demonstrating tremendous progress while developers continue struggling with CMC, analytical, process development, and manufacturing challenges.

At the Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit on November 18-19, 2021, topics that experts from the industry will discuss include:

• Important aspects of establishing an efficient and consistent CMC (Chemistry Manufacturing Controls) strategy
• Controlling a product’s CQAs (Critical Quality Attributes) by controlling the process’ CPPs (Critical Process Parameters)
• Key factors in easing the complexity of vector development and production
• Critical elements of controlling a manufacturing process for CGTP (Cell and Gene Therapy Products)